Skip to main content

Table 1 Demographic and clinical characteristics of the asthma group and normal control groups

From: Expression levels of plasma exosomal miR-124, miR-125b, miR-133b, miR-130a and miR-125b-1-3p in severe asthma patients and normal individuals with emphasis on inflammatory factors

 

Control (n = 30)

Severe asthma (n = 30)

P-value

Age

39.23 ± 10.17

42.13 ± 9.41

0.26

Sex (M/F)

13/17(43.3/56.7%)

12/18 (40/60%)

–

Age of asthma onset (Year)

–

31.90 ± 10.55

 

FEV1 (% predicted) ± SD

99.19 ± 10.99

51.37 ± 16.10

 < 0.0001

FVC (% predicted) ± SD

94.02 ± 8.39

63.50 ± 14.84

 < 0.0001

FEV1/FVC

0.85 ± 0.59

0.69 ± 0.11

 < 0.0001

BMI (Mean ± SD)

22.46 ± 2.28

23.30 ± 2.04

0.14

Blood eosinophil X 109 per L

0.09 ± 0.04

0.52 ± 0.21

 < 0.0001

Medication requirements (n)

ICS(LABA and LAMA) / ICS + OCS

–

10/20

–

Atopic (%)

Non

80.0 (n = 24)

–

Serum IgE IU/mL

39.32 ± 5.33

232.8 ± 25.79

 < 0.0001

  1. Asthma patients were divided into two groups according to the type of medication. One group was under Inhaled corticosteroid (ICS) and the other group was under ICS + Oral corticosteroid (OCS) therapy
  2. Normal controls had no history of predisposing to any chronic or inflammatory disease. Forced expiratory volume in 1 s (FEV1%) and Forced vital capacity (FVC %) detected. Atopic Determined by allergen skin prick tests. The p-value < 0.05 is considered significant